Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Principal Investigator, Dr Bertram Pitt (University of Michigan, US) for an insightful discussion on the FIGARO-DKD Trial presented at ESC Congress 2021.

The aim of study was to asses whether finerenone (Bayer), nonsteroidal mineralocorticoid receptor antagonist (MRA), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placebo. The study showed that finerenone improves outcomes in patients with mild-to-moderate kidney disease and diabetes.

Recorded remotely from Ann Arbor and Hamilton, 2021.

Editor: Mirjam Boros